管理無作為方式による成人急性白血病の化学療法

概要

論文の詳細を見る
In an attempt to establish the treatment system for adult acute leukemia, the effects of multicombination regimens using new agents currently developed in Japan have been studied in a prospective randomized cooperative trial supported by a Grant-in-Aid from Japanese Foundation for Multidisplinary Treatment of Cancer (chaiman: Dr. Kiyoji Kimura). The combined drugs used for AML were as follows: regimenA; BH-AC+DNR+6MP+PSL (BH-AC·DMP) or regimen B; BH-AC+ACM+6MP+PSL (BH-AC·AMP). The drugs used for ALL were regimen C; ADM+VCR+PSL (AdVP) or regimen D; ADM+VCR+L-ASP+PSL (L-AdVP). The 58 institutions are involved in this study. Since April, 1983 to August, 1984, 505 adults with acute leukemia, previously untreated, have been entered. of them the remission induction therapy have been completed in 253 patients, of whom 94 evaluable patients had regimen A, 87 regimen B, 36 regimen C and 36 regimen D, respectively. There were no statistical differences as to age, sex, FAB classification or hematological findings between group A and group B or group C and Group D. The remission rate of each group was as follows: 68% in group A, 55% in group B, 58% in group C and 67% in group D. Although there were no statistical differences as to remission durations between group A and group B or group C and group D, the survival time of group A was superior to that of group B at the present time (p<0.01).
一般社団法人日本血液学会の論文